Netmeds First Membership
Quick Links
Introduction About WELBUSOL 1.25 INHALATION SOLUTION
WELBUSOL 1.25 INHALATION SOLUTION contains Levosalbutamol which belongs to the group of medicines called Bronchodilators. It is indicated in the management or management of bronchospasm (constriction of airways) in adults, adolescents, and children between 6-11 years old with reversible obstructive airway disease.
Your doctor might ask you to take several diagnostic tests before starting the management with WELBUSOL 1.25 INHALATION SOLUTION.
It should be used with caution in patients having cardiovascular disorders (coronary insufficiency, cardiac arrhythmias, and high blood pressure), kidney diseases, epilepsy, overactive thyroid gland, and diabetes.
Caution must be exercised while using WELBUSOL 1.25 INHALATION SOLUTION in pregnant and breast-feeding women. Consult with your doctor before using.
WELBUSOL 1.25 INHALATION SOLUTION is not recommended for use in children below 6 years of age. Consult your doctor immediately if you experience any side effects.
Uses Of WELBUSOL 1.25 INHALATION SOLUTION
- Used to manage bronchospasm (constriction of airways) in reversible obstructive airway disease
How WELBUSOL 1.25 INHALATION SOLUTION Works
WELBUSOL 1.25 INHALATION SOLUTION helps in the management of bronchospasm acts by relaxing smooth muscle in the bronchial tubes (airway) to increase air flow and relieve shortness of breath by activation of an enzyme which inhibits the release of cells called mast cells which are responsible for causing asthma.
How to use WELBUSOL 1.25 INHALATION SOLUTION
Use WELBUSOL 1.25 INHALATION SOLUTION as advised by your physician. It is for oral inhalational use only. It is administered by nebulisation using with nebuliser (with a face mask or mouthpiece) which is connected to an air compressor. Your doctor will guide on how to use the nebuliser. Do not exceed the recommended dose of WELBUSOL 1.25 INHALATION SOLUTION. Check the label for directions before use.
Your doctor will decide the correct dose and duration of WELBUSOL 1.25 INHALATION SOLUTION for you depending upon your age, body weight and disease condition.
Side Effects Of WELBUSOL 1.25 INHALATION SOLUTION
Rare
Stop using WELBUSOL 1.25 INHALATION SOLUTION and inform your doctor immediately if you experience any of the following side effects:
- sudden shortness of breath (constriction of airways)
- asthma getting worsen
- severe allergic rection presenting as swelling of the face, throat or tongue, hives, rash, breathing problems
- heart problems (changes in heart rate or blood pressure)
- low potassium levels in blood
Warning & Precautions
Pregnancy
WELBUSOL 1.25 INHALATION SOLUTION should be used with caution in pregnant women or women planning to have a baby as safety and effectiveness to the baby and mother has not been established yet. Dose will be adjusted by your doctor. Consult your doctor before using it.
Breastfeeding
WELBUSOL 1.25 INHALATION SOLUTION should be used with caution in breastfeeding women as it is not known if WELBUSOL 1.25 INHALATION SOLUTION passes through mother’s milk. Consult your doctor before using it.
Kidney
WELBUSOL 1.25 INHALATION SOLUTION should be used with caution in patients with kidney problems. Consult your doctor before using it.
Allergy
Do not use WELBUSOL 1.25 INHALATION SOLUTION if you are allergic to Levosalbutamol or any other ingredients of this medicine.
Heart Disease
WELBUSOL 1.25 INHALATION SOLUTION should be used with caution in patients with heart diseases such as coronary insufficiency, irregular heartbeat, and high blood pressure. Consult your doctor before using.
Others
Before using WELBUSOL 1.25 INHALATION SOLUTION tell your doctor if you have:
- epilepsy
- thyroid problems
- diabetes
Use in pediatrics:
WELBUSOL 1.25 INHALATION SOLUTION has not been shown to be safe and effective in children younger than 6 years of age. Consult your doctor before using.
Use in geriatrics:
Your doctor will decide the correct dose and duration of the management with WELBUSOL 1.25 INHALATION SOLUTION for you depending upon your age, health condition and body weight. Kidney function will be monitored. Consult your doctor before using.
Interactions
A. Drug–Drug Interactions:
Before using WELBUSOL 1.25 INHALATION SOLUTION inform your doctor if you are taking any of the following medicine:
- other short acting bronchodilators such as albuterol, terbutaline (used to manage asthma)
- beta blockers such as metoprolol, propranolol (used to manage irregular heartbeat)
- digoxin (used to manage heart diseases)
- diuretics (water medicines) such as furosemide, chlorothiazide
- isocarboxazid, tricyclic antidepressants such as nortriptyline, amitriptyline (used to manage depression)
- halothane, enflurane, isoflurane, desflurane, sevoflurane (used as anaesthetics)
- corticosteroids (anti-inflammatory drug Ex. dexamethasone, hydrocortisone)
Overdosage:
If you or anyone else accidentally use too much of WELBUSOL 1.25 INHALATION SOLUTION, consult your doctor immediately or visit the nearby hospital. The symptoms of overdosage of WELBUSOL 1.25 INHALATION SOLUTION are fastened heart rate, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, and sleeplessness.
Synopsis
| Drug | : | Levosalbutamol |
| Pharmacological Category | : | Beta Agonists |
| Therapeutic Indication | : | Bronchospasm in Reversible Obstructive Airway Disease |
| Dosage Forms | : | Tablet, Syrup, Transpules, Respules, Solution, Rotacaps, Inhalers, Nexhalers, Inhalation solution |
More Information
- Keep WELBUSOL 1.25 INHALATION SOLUTION out of reach of children
- Store below at room temperature 30°C
FAQs About WELBUSOL 1.25 INHALATION SOLUTION
What is WELBUSOL 1.25 INHALATION SOLUTION and why is it prescribed?
WELBUSOL 1.25 INHALATION SOLUTION contains Levosalbutamol which belongs to the group of medicines called Bronchodilators. It is indicated in the management or management of bronchospasm (constriction of airways) in adults, adolescents, and children between 6-11 years old with reversible obstructive airway disease.
Can WELBUSOL 1.25 INHALATION SOLUTION be given to patients having heart disease?
WELBUSOL 1.25 INHALATION SOLUTION may cause fastened heart rate. It should be used with caution in patients with heart diseases such as coronary insufficiency, irregular heartbeat, and high blood pressure. Consult your doctor before using.
Is it safe to use WELBUSOL 1.25 INHALATION SOLUTION in diabetic patients?
WELBUSOL 1.25 INHALATION SOLUTION may cause an increase in blood sugar level. Therefore, caution must be exercised while using WELBUSOL 1.25 INHALATION SOLUTION in diabetic patients and should be kept under close observation. Consult your doctor before using.
How to use WELBUSOL 1.25 INHALATION SOLUTION?
Use WELBUSOL 1.25 INHALATION SOLUTION as advised by your physician. It is for oral inhalational use only. It is administered by nebulisation using with nebuliser (with a face mask or mouthpiece) which is connected to an air compressor. Your doctor will decide the correct dose and duration of WELBUSOL 1.25 INHALATION SOLUTION for you depending upon your age, body weight and disease condition.
Can I stop using WELBUSOL 1.25 INHALATION SOLUTION if I feel better?
You should not stop using WELBUSOL 1.25 INHALATION SOLUTION until your doctor asks you to. Keep using WELBUSOL 1.25 INHALATION SOLUTION for the whole time it has been prescribed to you. If you wish to discontinue, ask for your doctor’s advice.
References
1. K.D. Tripathi. Respiratory System Drugs. Essentials of medical pharmacology. Seventh edition. 2013. Page – 222.
2. Mukesh Kumar Gupta, Meenu Singh. Evidence based review on Levosalbutamol. NIH National Library of Medicine, National centre for biotechnology information. Pubmed.gov. February 2007. [Accessed on 18th July 2022] https://pubmed.ncbi.nlm.nih.gov/17337829/
3. J L Schlienger, M J Compagnie, P Dellenbach, F Stephan. Metabolic risks of salbutamol in diabetic patients. A study using somatostatin (author's transl). NIH National Library of Medicine, National centre for biotechnology information. Pubmed.gov. September 1980. [Accessed on 18th July 2022] https://pubmed.ncbi.nlm.nih.gov/6106923/
4. NIH National Library of Medicine, National centre for biotechnology information. Pubchem. Levalbuterol. [Accessed on 18th July 2022] https://pubchem.ncbi.nlm.nih.gov/compound/Levalbuterol
5. Cipla Ltd. Levolin Respules. Ciplamed. [Revised in February 2021] [Accessed on 18th July 2022] https://www.ciplamed.com/content/levolin-respules
6. Drugbank. Levosalbutamol. [Revised in October 2021] [Accessed on 19th July 2022] https://go.drugbank.com/drugs/DB13139
Useful Diagnostic Tests
- Chest X ray
- Pulmonary Function Test
- Kidney function test
Author Details
